Table 4.
Group | n | MFI (CEA) | MFI (CA199) | MFI (CA125) | MFI (CA242) |
Age (yr) | |||||
≥ 50 | 45 | 9.5 ± 4.3 | 239.1 ± 324.6 | 55.9 ± 86.6 | 39.9 ± 42.9 |
< 50 | 33 | 9.2 ± 2.7 | 236.9 ± 319.4 | 54.6 ± 78.9 | 39.9 ± 47.3 |
Sex | |||||
Male | 30 | 9.3 ± 6.6 | 234.6 ± 356.9 | 54.8 ± 81.7 | 38.5 ± 47.1 |
Female | 48 | 9.4 ± 3.8 | 240.4 ± 298.7 | 55.7 ± 89.5 | 40.8 ± 49.9 |
Tumor position | |||||
Neck | 37 | 8.5 ± 3.9 | 262.2 ± 177.8b | 62.1 ± 47.0b | 42.5 ± 45.9b |
Body | 23 | 5.2 ± 4.2 | 28.3 ± 20.7 | 56.9 ± 99.7 | 19.0 ± 21.6 |
Bottom | 5 | 3.3 ± 2.6 | 27.6 ± 2.4b | 14.5 ± 6.5b | 8.5 ± 2.9b |
Cystic duct | 13 | 21.5 ± 25.1 | 622 ± 196.9 | 49.0 ± 32.9 | 81.7 ± 56.7 |
Staging | |||||
II | 7 | 3.2 ± 2.2 | 66.1 ± 6.3a | 17.7 ± 7.7a | 8.4 ± 3.3a |
IIIA | 10 | 2.0 ± 0.9 | 89.5 ± 8.2 | 47.3 ± 38.2 | 10.2 ± 9.9 |
IIIB | 33 | 6.9 ± 6.4 | 205.5 ± 33.9a | 59.6 ± 114.1a | 22 ± 22.6a |
IVA | 6 | 3.5 ± 3.3 | 383.6 ± 55.5a | 58.1 ± 25.5a | 55.2 ± 25.3a |
IVB | 22 | 19.9 ± 9.1 | 418.7 ± 316.5a | 64.1 ± 50.5a | 86.2 ± 56.9a |
Tumor size | |||||
> 5 cm | 20 | 9.6 ± 2.2 | 768.1 ± 272.9a | 82.9 ± 21.9a | 81.8 ± 53.1a |
≤ 5 cm | 58 | 9.3 ± 1.2 | 55.4 ± 68.7a | 45.8 ± 10.1a | 25.5 ± 32.9a |
Pathological type | |||||
Highly differentiated | 8 | 3.0 ± 2.0 | 68.9 ± 5.9a | 16.7 ± 7.7a | 8.7 ± 3.1a |
Moderately differentiated | 54 | 6.9 ± 5.9 | 142.3 ± 200.4 | 49.9 ± 9.9 | 33.8 ± 41.3 |
Poorly differentiated | 11 | 3.5 ± 2.5 | 649.1 ± 209.1a | 84.0 ± 29.4a | 73.4 ± 58.9a |
Carcinoid | 2 | 20.9 ± 14.6 | 766.3 ± 330.5a | 121.3 ± 45.2a | 62.7 ± 9.4a |
Squamous cell carcinoma | 2 | 107.5 ± 69.1 | 334.4 ± 14.9a | 116.0 ± 103.1a | 108.5 ± 58.7a |
Signet ring cell carcinoma | 1 | 31 | 1000a | 89.3a | 69.3a |
Results are mean ± SD.
P < 0.05,
P < 0.01 vs control group. MFI: Mean fluorescence intensity; CA: Cancer antigen; CEA: Carcinoembryonic antigen.